Floatz logo

Tsc-204-A0201

HPV - Anogenital Human Papilloma Virus Infection

TScan Therapeutics, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the HPV - Anogenital Human Papilloma Virus Infection cohort.

Asset / SponsorPhaseRating
9vhpv vaccine
Merck Sharp & Dohme LLC
Phase 3BB
v503
Merck Sharp & Dohme LLC
Phase 3BB
9-valent human papillomavirus recombinant vaccine
Xiamen University
Phase 3B
Tsc-201-B0702
TScan Therapeutics, Inc.
Phase 1CC
Tsc-200-A0201
TScan Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

Tsc-204-A0201 is also rated in:

cervical carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
vaginal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →